Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR8613748

· D

0d2b8ee4-e7aa-5d1c-bc62-34267717eb24

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • WNT_BETA_CATENIN_SIGNALING+0.360
  • NOTCH_SIGNALING+0.220
  • MYC_TARGETS_V2+0.200
  • HEDGEHOG_SIGNALING+0.080
  • SPERMATOGENESIS+0.080
  • MITOTIC_SPINDLE+0.050
  • KRAS_SIGNALING_DN+0.020
  • MYC_TARGETS_V1+0.010
  • MYOGENESIS+0.010
  • APICAL_JUNCTION-0.040

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.670
  • INTERFERON_GAMMA_RESPONSE-0.560
  • TNFA_SIGNALING_VIA_NFKB-0.410
  • MTORC1_SIGNALING-0.390
  • INFLAMMATORY_RESPONSE-0.380
  • ALLOGRAFT_REJECTION-0.370
  • TGF_BETA_SIGNALING-0.350
  • ANDROGEN_RESPONSE-0.340
  • IL2_STAT5_SIGNALING-0.340
  • IL6_JAK_STAT3_SIGNALING-0.340

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_0719_T1_RNA
breast-umap@18
A0.896
2s0102877
melanoma-umap@29
0.892
3TCGA-90-A4ED-01A-31R-A24Z-07
lung-landscapes@6
cohortMD10.883
4SRR8518450
breast-umap@18
A0.881
5TCGA-D6-6827-01A-11R-1915-07
head-neck@1
0.868
6GSM5359422
bladder-landscape@3
0.865
7SRR1313141
breast-umap@18
E0.863
8MDT-AP-0396
medullo-epn-umap@date-based
MedMedulloblastoma0.859
9ea635e80-1225-4f52-a6cf-8f4c20201240
colon-landscapes@1
0.859
10SRR650166
bladder-landscape@3
0.856

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 9 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
WNT_BETA_CATENIN_SIGNALING0.360Inavolisib— uncovered
NOTCH_SIGNALING0.220Inavolisib— uncovered
MYC_TARGETS_V20.200Idelalisib— uncovered
HEDGEHOG_SIGNALING0.080Inavolisib— uncovered
SPERMATOGENESIS0.080Inavolisib— uncovered
MITOTIC_SPINDLE0.050Inavolisib— uncovered
KRAS_SIGNALING_DN0.020Remibrutinib— uncovered
MYC_TARGETS_V10.010Inavolisib— uncovered
MYOGENESIS0.010Inavolisib— uncovered